This multidisciplinary research project will test the novel hypothesis that Dll4-triggered signaling contributes to the pathogenesis of atherosclerosis. We will focus on macrophage-derived proteolytic activity, the key feature typical of arterial remodeling associated with the onset of acute coronary events. We previously reported that Dll4 (a ligand of Notch signaling) promotes expression or activation of pro-inflammatory factors (e.g., iNOS, NF-?B) in cultured macrophages. The role of Notch signaling is strictly cell-type- and context- dependent, and in vivo functions of the Notch pathway in macrophages remain unknown. Using mouse models, the present study will explore the role of the Dll4-Notch axis in activation of plaque macrophages and development of atherosclerosis.
Specific Aim 1 will examine whether Dll4 antibody administration attenuates macrophage activation and atherogenesis in Ldlr-/- mice. We will also use macrophage-targeted in vivo delivery of Dll4 siRNA to determine the relative contribution of macrophage Dll4.
Specific Aim 2 will address the role of Notch3 based on our data that suggested its pro-atherogenic role. In Notch3-transgenic and null mice to test the hypothesis that this Notch receptor promotes macrophage activation and athrogenesis. These complementary studies will offer novel mechanisms of macrophage activation and atherosclerosis, and will also provide proof of concept that the Dll4-Notch3 pathway can be a therapeutic target for atherosclerosis, its complications, and other vascular diseases.
Inflammation in coronary arteries triggers acute complications of atherosclerosis (e.g., heart attack). However, the mechanism for arterial inflammation remains incompletely understood. We previously used cell culture systems that Delta-like 4 (Dll4) triggers inflammation. The present study will perform mouse experiments to dissect the new mechanisms of inflammation and atherosclerosis. The potential outcomes will offer new therapeutic targets for vascular diseases and contribute to preventive cardiovascular medicine.
|Koga, Jun-ichiro; Aikawa, Masanori (2014) Application of anti-ligand antibodies to inhibit Notch signaling. Methods Mol Biol 1187:335-42|
|Eltoukhy, Ahmed A; Sahay, Gaurav; Cunningham, James M et al. (2014) Niemann-Pick C1 affects the gene delivery efficacy of degradable polymeric nanoparticles. ACS Nano 8:7905-13|
|Itou, Takahiro; Maldonado, Natalia; Yamada, Iwao et al. (2014) Cystathionine ýý-lyase accelerates osteoclast differentiation: identification of a novel regulator of osteoclastogenesis by proteomic analysis. Arterioscler Thromb Vasc Biol 34:626-34|
|Yabusaki, Katsumi; Faits, Tyler; McMullen, Eri et al. (2014) A novel quantitative approach for eliminating sample-to-sample variation using a hue saturation value analysis program. PLoS One 9:e89627|
|Miyazaki, Tetsuro; Chiuve, Stephanie; Sacks, Frank M et al. (2014) Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One 9:e94073|
|Fukuda, Daiju; Aikawa, Masanori (2013) Expanding role of delta-like 4 mediated notch signaling in cardiovascular and metabolic diseases. Circ J 77:2462-8|
|Koga, Jun-ichiro; Aikawa, Masanori (2012) Crosstalk between macrophages and smooth muscle cells in atherosclerotic vascular diseases. Vascul Pharmacol 57:24-8|